BioSpace News Archive

Second Quarter: Quarterly sales, operating profit, and earnings per share were all company records Sales were $590 million, an 11% increase over prior year Operating profit was $166 million, a 33% increase over prior year Earnings were $2.12 per diluted share, a 34% increase over prior year

MicroGen Diagnostics , the industry leader in providing next-generation DNA sequencing (NGS) for clinical diagnostics, has introduced OrthoKEY, an innovative approach to address current clinical shortcomings in the diagnosis of orthopedic infections.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces that the first patient has been successfully enrolled

Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab to treat patients with recurrent glioblastoma (rGBM) has been accepted for review by China NMPA.